"description","id","label","instanceType","name","rationale","uuid:ID"
"The main design for the study","StudyDesign_1","","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","572f09a7-22db-4753-8b75-4d123983e80e"
